Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 22, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Follicular LymphomaRefractory B-Cell LymphomaRelapsed Non-Hodgkin Lymphoma
Interventions
DRUG

Chidamide combined with Linperlisib

Specified dose on specified days: Cedarbenzamide (C) 20mg orally twice weekly, Limplica (L) 80mg once daily, 2 weeks on 2 weeks off, Repeat on day 28.

Trial Locations (1)

361000

RECRUITING

Bing Xu, Xiamen

All Listed Sponsors
collaborator

Fujian Provincial Hospital

OTHER

collaborator

Fujian Cancer Hospital

OTHER_GOV

collaborator

Zhangzhou Affiliated Hospital of Fujian Medical University

OTHER

collaborator

Jieyang People's Hospital

OTHER

collaborator

Dongguan People's Hospital

OTHER_GOV

collaborator

Huizhou Municipal Central Hospital

OTHER

collaborator

The First Affiliated Hospital with Nanjing Medical University

OTHER

collaborator

Sun Yat-sen University

OTHER

collaborator

Shanxi Province Cancer Hospital

OTHER

lead

The First Affiliated Hospital of Xiamen University

OTHER